Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)

IC₅₀ values (mean ±SD in μM) of <i><i>in vitro</i></i> DPPH-radical scavenging properties vs. ascorbic acid and antiinflammation propensities vs. indomethacin of the tes... by MohammedBashar Al-Qazzan (22439236)

Subjects:

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years.doc by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years.tif by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Homogenizing experiment: Mean fecal egg counts (FECs), mean relative differences from the grand mean FECs per sample (over 7 observations), standard deviation of the relative diffe... by Felix Bosch (10024550)

Decreased membrane localization of myrGFP in <i>ACBD6</i>-deficient cells. by Eric Soupene (64584)

Integrin expression decreased in treated tumors. by Anthony B. Eason (6294305)

Pharmacological inhibition of EGFR decreases early fungal burden and reduces the inflammatory response. by Marc Swidergall (185453)

Intake and digestibility during two digestibility trials (1: 20–28 d; 2: 50–56 d) of dairy calves fed different additives in the starter feed (n = 15). by Luisa F. L. Salazar (6664121)

miR-450a decreases TMEM182 by directly targeting 3'-UTR. by En-Wei Hsing (154990)

Effect of atipamezole or efaroxan (1 mg·kg⁻¹) (Protocol 2). by Yoichiro Kitajima (4319455)

Subjects:

Whole sample storing experiment: Mean FECs of day 0, day 1 and day 2 for hookworm, <i>A</i>. <i>lumbricoides</i> and <i>T</i>. <i>trichiura</i>. by Felix Bosch (10024550)

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial by Daniëlle B. P. Eekers (5560430)

Effect of cilostazol on the serum ALT (A), AST (B) levels in rats with TAA-induced liver fibrosis. by Sally A. El Awdan (710176)

Effect of cilostazol on liver α-SMA (A) and COL-1 (B) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Fig 1 - by Dalia Zaafar (6693017)

Subjects:

Fig 3 - by Dalia Zaafar (6693017)

Subjects:

HoxA9-ER directly represses <i>Cebpa</i> gene expression in myeloid cells. by Lei Peng (260321)

Subjects:

Effect of sorafenib alone or added to hesperetin on the expression of NLRP3 inflammasome and TLR4 via western blotting in different groups. by Dalia Zaafar (6693017)

Subjects:

Fig 5 - by Dalia Zaafar (6693017)

Subjects: